Kai-ni Shen

Kai-ni Shen

Peking Union Medical College Hospital, Peking Union Medical College
Beijing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 40 publications

Attenuated prognostic discrimination among Mayo stages I-IIIa and improved survival in stage IIIb in the daratumumab era: a real-world study of newly diagnosed AL amyloidosis.

Attenuated prognostic discrimination among Mayo stages I-IIIa and improved survival in stage IIIb in the daratumumab era: a real-world study of newly diagnosed AL amyloidosis.

Journal: Leukemia & lymphoma

Published: June 07, 2026

Case Report: Erdheim-Chester disease with liver involvement successfully treated with trametinib.

Case Report: Erdheim-Chester disease with liver involvement successfully treated with trametinib.

Journal: Frontiers in oncology

Published: November 05, 2025

Hepatic Response Dynamics in Newly Diagnosed Patients with Light-chain Amyloidosis: A Retrospective Cohort Study.

Hepatic Response Dynamics in Newly Diagnosed Patients with Light-chain Amyloidosis: A Retrospective Cohort Study.

Journal: Advances in therapy

Published: October 15, 2025

Efficacy of venetoclax in the treatment of relapsed/refractory light-chain amyloidosis.

Efficacy of venetoclax in the treatment of relapsed/refractory light-chain amyloidosis.

Journal: Annals of hematology

Published: September 15, 2025

Real-World Comparative Analysis of Polatuzumab Vedotin-Based Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone versus Standard Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Diffuse Large B-Cell Lymphoma: A Propensity Score-Matched Cohort Study.

Real-World Comparative Analysis of Polatuzumab Vedotin-Based Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone versus Standard Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Diffuse Large B-Cell Lymphoma: A Propensity Score-Matched Cohort Study.

Journal: Oncology

Published: September 10, 2025

Langerhans cell histiocytosis with mesenteric involvement successfully treated with trametinib: a rare cause of small intestine obstruction.

Langerhans cell histiocytosis with mesenteric involvement successfully treated with trametinib: a rare cause of small intestine obstruction.

Journal: International journal of hematology

Published: May 04, 2025

Hereditary transthyretin cardiac amyloidosis with Glu109Lys mutation presenting with low sensitivity to 99mTc pyrophosphate in scintigraphy: a case description.

Hereditary transthyretin cardiac amyloidosis with Glu109Lys mutation presenting with low sensitivity to 99mTc pyrophosphate in scintigraphy: a case description.

Journal: Quantitative imaging in medicine and surgery

Published: December 22, 2024

Real-world data of siltuximab for Chinese patients with iMCD: combination with BCD regimen as a potential approach for severe cases.

Real-world data of siltuximab for Chinese patients with iMCD: combination with BCD regimen as a potential approach for severe cases.

Journal: Annals of hematology

Published: June 07, 2024

Cardiac Response Dynamics in Newly Diagnosed Light-Chain Amyloidosis Patients With Early and High-Quality Hematologic Response.

Cardiac Response Dynamics in Newly Diagnosed Light-Chain Amyloidosis Patients With Early and High-Quality Hematologic Response.

Journal: JACC. Asia

Published: April 24, 2024

Disseminated juvenile xanthogranuloma harbouring a GAB2::BRAF fusion successfully treated with trametinib: a case report.

Disseminated juvenile xanthogranuloma harbouring a GAB2::BRAF fusion successfully treated with trametinib: a case report.

Journal: The British journal of dermatology

Published: March 02, 2024

Long-term outcomes of newly diagnosed POEMS syndrome patients who received first-line lenalidomide-based therapy.

Long-term outcomes of newly diagnosed POEMS syndrome patients who received first-line lenalidomide-based therapy.

Journal: Haematologica

Published: February 19, 2024

Efficacy and safety of daratumumab plus bortezomib and dexamethasone in newly diagnosed Mayo 2004 stage IIIA or IIIB light-chain amyloidosis: a prospective phase II study.

Efficacy and safety of daratumumab plus bortezomib and dexamethasone in newly diagnosed Mayo 2004 stage IIIA or IIIB light-chain amyloidosis: a prospective phase II study.

Journal: Haematologica

Published: February 03, 2024

Showing 1-12 of 40

Last Updated: 09/26/2026